X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (37) 37
index medicus (29) 29
female (27) 27
male (26) 26
melanoma (22) 22
adult (21) 21
aged (20) 20
middle aged (20) 20
oncology (19) 19
immunotherapy (17) 17
melanoma - drug therapy (15) 15
pembrolizumab (15) 15
cancer (14) 14
aged, 80 and over (13) 13
care and treatment (13) 13
mutation (12) 12
ipilimumab (11) 11
melanoma - pathology (11) 11
metastasis (11) 11
anti-pd-1 (10) 10
article (10) 10
melanoma - immunology (10) 10
metastatic melanoma (10) 10
safety (10) 10
tumors (10) 10
abridged index medicus (9) 9
programmed cell death 1 receptor - antagonists & inhibitors (9) 9
research (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
nivolumab (8) 8
patients (8) 8
adolescent (7) 7
antibodies, monoclonal, humanized - administration & dosage (7) 7
chemotherapy (7) 7
disease-free survival (7) 7
melanoma - genetics (7) 7
melanoma - therapy (7) 7
neoplasm staging (7) 7
squamous cell carcinoma (7) 7
survival (7) 7
therapy (7) 7
cell lung-cancer (6) 6
clinical trials (6) 6
dermatology (6) 6
drug therapy (6) 6
follow-up studies (6) 6
medical prognosis (6) 6
metastases (6) 6
open-label (6) 6
pd-1 (6) 6
prognosis (6) 6
proto-oncogene proteins b-raf - genetics (6) 6
retrospective studies (6) 6
skin neoplasms - drug therapy (6) 6
skin neoplasms - pathology (6) 6
survival rate (6) 6
young adult (6) 6
antibodies, monoclonal - administration & dosage (5) 5
antibodies, monoclonal - therapeutic use (5) 5
antibodies, monoclonal, humanized - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
apoptosis (5) 5
attention - physiology (5) 5
auditory (5) 5
cancer therapies (5) 5
medicine, general & internal (5) 5
patient outcomes (5) 5
programmed cell death 1 receptor - immunology (5) 5
proto-oncogene proteins b-raf - antagonists & inhibitors (5) 5
skin cancer (5) 5
treatment outcome (5) 5
usage (5) 5
antibodies, monoclonal, humanized - adverse effects (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
antineoplastic agents - therapeutic use (4) 4
attention (4) 4
brain neoplasms - secondary (4) 4
cortex (4) 4
cytotoxicity (4) 4
disease progression (4) 4
genetic aspects (4) 4
head and neck cancer (4) 4
health aspects (4) 4
imidazoles - administration & dosage (4) 4
imidazoles - adverse effects (4) 4
immune response (4) 4
immune system (4) 4
immunology (4) 4
intermodal (4) 4
kaplan-meier estimate (4) 4
melanoma - metabolism (4) 4
mutations (4) 4
oximes - administration & dosage (4) 4
oximes - adverse effects (4) 4
resistance (4) 4
solid tumors (4) 4
toxicity (4) 4
trial (4) 4
uveal melanoma (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 11, pp. 1087 - 1095
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 2017, Volume 109, Issue 1
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 2, pp. 134 - 144
Journal Article
JAMA, ISSN 0098-7484, 04/2016, Volume 315, Issue 15, pp. 1600 - 1609
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 18, pp. 1694 - 1703
The combination of a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with metastatic melanoma produced a significantly higher response... 
CELL LUNG-CANCER | METASTATIC MELANOMA | MEDICINE, GENERAL & INTERNAL | EFFICACY | PATHWAY | SAFETY | KINASE | RESISTANCE | DOSE-ESCALATION TRIAL | RAF INHIBITORS | IMPROVED SURVIVAL | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Imidazoles - pharmacokinetics | Fever - chemically induced | Drug Therapy, Combination - adverse effects | Melanoma - genetics | Adult | Female | Imidazoles - therapeutic use | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | MAP Kinase Signaling System - drug effects | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged | Pyridones - therapeutic use | Mutation | Pyridones - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Melanoma | Product/Service Evaluations | Research | Antineoplastic agents | Antimitotic agents | Gene mutations | Causes of | Genetic aspects | Dosage and administration | Drug therapy, Combination | Drug therapy | Cell survival | Protein kinase | Skin diseases | MAP kinase | Kinases | Patients | Drug dosages | Fever | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 09/2016, Volume 126, Issue 9, pp. 3447 - 3452
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2018, Volume 379, Issue 8, pp. 722 - 730
Journal Article
Nature Genetics, ISSN 1061-4036, 02/2015, Volume 47, Issue 3, pp. 250 - 256
Resistance to RAF-and MEK-targeted therapy is a major clinical challenge(1-4). RAF and MEK inhibitors are initially but only transiently effective in some but... 
COLON-CANCER | SURVIVAL | LUNG | ACTIVATION | INHIBITION | MELANOMA | SIGNALING PATHWAY | TRANSCRIPTION | GENETICS & HEREDITY | BRAF | KRAS | Humans | Molecular Targeted Therapy | Phosphoproteins - metabolism | Gene Knockdown Techniques | Heterografts | MAP Kinase Signaling System - genetics | HEK293 Cells | Female | MAP Kinase Kinase Kinases - antagonists & inhibitors | Protein-Serine-Threonine Kinases - metabolism | Proto-Oncogene Proteins B-raf - metabolism | MAP Kinase Kinase Kinases - genetics | Protein-Serine-Threonine Kinases - genetics | MAP Kinase Kinase Kinases - metabolism | Phosphoproteins - genetics | Mice, SCID | HT29 Cells | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Drug Resistance, Neoplasm - genetics | Animals | MAP Kinase Signaling System - drug effects | Proto-Oncogene Proteins B-raf - genetics | Adaptor Proteins, Signal Transducing - genetics | Cell Line, Tumor | Mice, Inbred NOD | Biomarkers, Tumor - genetics | Mice | Protein Kinase Inhibitors - pharmacology | Mutation | Adaptor Proteins, Signal Transducing - metabolism | Genes, ras | Antimitotic agents | Gene mutations | Genetic aspects | Research | Antineoplastic agents | Drug resistance | Health aspects | Thyroid cancer | Lung cancer | Colorectal cancer | Melanoma | Kinases | Charitable foundations | Cancer therapies | Design of experiments | Tumors
Journal Article
Cancer, ISSN 0008-543X, 11/2016, Volume 122, Issue 21, pp. 3354 - 3362
Journal Article
Nature, ISSN 0028-0836, 01/2018, Volume 553, Issue 7688, pp. 347 - 350
Journal Article
Melanoma Management, ISSN 2045-0885, 05/2017, Volume 4, Issue 2, pp. 79 - 82
Despite this limitation, first-line treatment with pembrolizumab or nivolumab plus ipilimumab is widely used, with clinicians in many cases extrapolating from... 
toxicity | pembrolizumab | nivolumab | safety | uveal melanoma | immunotherapy | PD-L1 | atezolizumab | PD-1 | Inflammatory bowel disease | Hepatitis | Immunoglobulins | Medical prognosis | Immunotherapy | Melanoma | Response rates | Diarrhea | Metastasis | Mutation | Cancer therapies
Journal Article
British Journal of Cancer, ISSN 0007-0920, 04/2017, Volume 116, Issue 9, pp. 1141 - 1147
Background: Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma. We developed and validated a clinical prediction scale for response... 
nivolumab | EFFICACY | SAFETY | advanced melanoma | TUMOR | CANCER-IMMUNOTHERAPY | pembrolizumab | METASTATIC MELANOMA | prediction scale | ONCOLOGY | immunotherapy | ANTI-PD-1 | T-CELLS | IPILIMUMAB | Clinical Study
Journal Article